Primary Record
Encequidar
- In stock
- 9,791 g
- Purity
- 98.8 %
- CAS
- 849675-66-7
Compound Identifiers & Properties
- CAS
- 849675-66-7
- PubChem CID
- 11399764
- SMILES
- COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)N4N=C(N=N4)C5=CC(=C(C=C5NC(=O)C6=CC(=O)C7=CC=CC=C7O6)OC)OC)OC
- Canonical SMILES
- COc1cc2c(cc1OC)CN(CCc1ccc(-n3nnc(-c4cc(OC)c(OC)cc4NC(=O)c4cc(=O)c5ccccc5o4)n3)cc1)CC2
Names & Synonyms
- Encequidar
- encequidarum
- 849675-66-7
- Encequidar [USAN]
- HM-30181
- HM30181
- Pgp inhibitor hm30181ak
- HM-30181-A
- ENCEQUIDAR [INN]
- HM30181AK
- Encequidar (USAN/INN)
- ENCEQUIDAR [WHO-DD]
- RefChem:590792
- HM-30181 free base
- Encequidar (HM30181)
- HM30181(Encequidar)?
- UNII-K4I4I996O4
- K4I4I996O4
- HM 30181A
- AHJUHHDDCJQACA-UHFFFAOYSA-N
- MFCD25976625
- orb1298944
- CHEMBL4594298
- SCHEMBL13822558
- SCHEMBL29386309
- EX-A3429A
- GTPL12787
- HM-30181A
- C38H36N6O7
- DTXSID501100387
- BCP25240
- HM30181A
- ZIB67566
- BDBM50567579
- s3431
- WHO 10861
- ZINC68014383
- AKOS025396246
- CS-6194
- DB14070
- HM30181;HM30181A
- SB18921
- CID11399764
- P-GLYCOPROTEIN INHIBITOR HM30181AK
- AC-36564
- AS-35283
- CID 11399764
- DA-64208
- HY-13646
- NS00072886
- Oraxol (encequidar methanesulfonate + paclitaxel)
- J2.313.227C
- Oratecan (encequidar methanesulfonate + irinotecan)
- D11782
- A857803
- N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
- Q27281950
- 4-Oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide
- N-[2-[2-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-2H-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-4H-1-benzopyran-2-carboxamide
- 4H-1-BENZOPYRAN-2-CARBOXAMIDE, N-(2-(2-(4-(2-(3,4-DIHYDRO-6,7-DIMETHOXY-2(1H)-ISOQUINOLINYL)ETHYL)PHENYL)-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL)-4-OXO-
- 4H-1-Benzopyran-2-carboxamide, N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-2H-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-
- N-[2-(2-{4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}-2h-1,2,3,4-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide
- ~{N}-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1~{H}-isoquinolin-2-yl)ethyl]phenyl]-1,2,3,4-tetrazol-5-yl]-4,5-dimethoxy-phenyl]-4-oxidanylidene-2,3-dihydrochromene-2-carboxamide
- 4-oxo-4H-chromen-2-carboxylic acid [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide
- 4-Oxo-4H-chromene-2-carboxylic acid [2-(2-4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide
- N-(2-(2-(4-(2-(3,4-DIHYDRO-6,7-DIMETHOXY-2(1H)-ISOQUINOLINYL)ETHYL)PHENYL)-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL)-4-OXO-4H-1-BENZOPYRAN-2-CARBOXAMIDE
- N-(2-(2-(4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-2H-1,2,3,4-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide
- N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl)phenyl)tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxochromene-2-carboxamide
- N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide
- N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide
- N-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl}-1,2,3,4-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
- N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxy-phenyl]-4-oxo-chromene-2-carboxamide
- N-[2-[3-[4-[2-[(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline)-2-yl]ethyl]phenyl]-3H-tetrazole-5-yl]-4,5-dimethoxyphenyl]-4-oxo-4H-1-benzopyran-2-carboxamide
- V5Q